Document:

EX-10.1

 Exhibit 10.1 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 22nd day of October, 2020,
by and among Senti Biosciences, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. 

RECITALS 

WHEREAS, the Company and certain of the Investors are parties to the Series B Preferred Stock Purchase Agreement of even date herewith
(as may be amended from time to time, the “Purchase Agreement”); 
 WHEREAS, the Company and certain of the
Investors previously entered into that certain Investors’ Rights Agreement dated February 9, 2018 (the “Prior Agreement”); and 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Investors to invest funds in the Company
pursuant to the Purchase Agreement, the Investors and the Company hereby agree that the Prior Agreement shall be amended and restated, superseded and replaced in its entirety, and that this Agreement shall govern the rights of the Investors to cause
the Company to register shares of Common Stock issuable to the Investors, and to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this
Agreement. 
 NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more
general partners or managing members of, or shares the same management company with, such Person, provided, however, that portfolio companies of any venture capital fund shall not be deemed “Affiliates” of such venture
capital fund. 
 1.2 “Board of Directors” means the board of directors of the Company. 

1.3 “Common Stock” means shares of the Company’s common stock, par value $0.0001 per share. 

1.4 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under
the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a
material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the
Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

  
 1 

 1.5 “Deemed Liquidation Event” has the meaning set forth in the Restated
Certificate. 
 1.6 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable
for (in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.7 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.8 “Excluded
Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an
SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a
registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.9 “Form S-1” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.10 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.11 “GAAP” means generally accepted
accounting principles in the United States. 
 1.12 “Holder” means any holder of Registrable Securities who is a party to
this Agreement. 
 1.13 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person
referred to herein. 
 1.14 “Initiating Holders” means, collectively, Holders who properly initiate a registration request
under this Agreement. 
 1.15 “IPO” means the Company’s first underwritten public offering of its Common Stock under
the Securities Act. 
 1.16 “Key Employee” means any executive-level employee (including, division director and vice
president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

  
 2 

 1.17 “Major Investor” means (a) prior to the Second Tranche Closing
(as defined in the Purchase Agreement), any Investor that, individually or together with such Investor’s Affiliates, holds at least 2,815,507 shares of Preferred Stock (or an equivalent number of shares of Common Stock issued upon conversion of
the Preferred Stock, but excluding Common Stock issued upon conversion of the Preferred Stock pursuant to the “Special Mandatory Conversion” provisions of the Restated Certificate), (b) immediately following the Second Tranche Closing
Deadline and prior to the Third Tranche Closing (each as defined in the Purchase Agreement), any Investor that, individually or together with such Investor’s Affiliates, holds at least 3,657,616 shares of Preferred Stock (or an equivalent
number of shares of Common Stock issued upon conversion of the Preferred Stock, but excluding Common Stock issued upon conversion of the Preferred Stock pursuant to the “Special Mandatory Conversion” provisions of the Restated Certificate)
and (c) from and after the Third Tranche Closing Deadline (as defined in the Purchase Agreement), any Investor that, individually or together with such Investor’s Affiliates, holds at least 4,591,038 shares of Preferred Stock (or an
equivalent number of shares of Common Stock issued upon conversion of the Preferred Stock, but excluding Common Stock issued upon conversion of the Preferred Stock pursuant to the “Special Mandatory Conversion” provisions of the Restated
Certificate). For the avoidance of doubt, the following holders shall be considered Affiliates of each other for purposes of determining the availability of Major Investor rights under this Agreement: Lux Ventures IV, L.P., Bryan White, CNSA LLC and
GRIDS Ventures I, Ltd. 
 1.18 “New Securities” means, collectively, all shares of equity securities of the Company, whether
or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.19 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.20 “Preferred Director” means any director of the Company that the holders of record of the Preferred
Stock are entitled to elect pursuant to the Restated Certificate. 
 1.21 “Preferred Stock” means, collectively, shares of
the Company’s Series A Preferred Stock and Series B Preferred Stock. 
 1.22 “QPO” has the meaning set forth in the
Restated Certificate. 
 1.23 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of
the Preferred Stock, excluding any Common Stock issued upon conversion of the Preferred Stock pursuant to the “Special Mandatory Conversion” provisions of the Restated Certificate and (ii) any Common Stock issued as (or issuable upon
the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases,
however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any
shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 
 1.24 “Registrable
Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly)
pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

  
 3 

 1.25 “Restated Certificate” means the Company’s Amended and Restated
Certificate of Incorporation, as may be amended or amended and restated from time to time. 
 1.26 “Restricted Securities”
means the securities of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 
 1.27
“SEC” means the Securities and Exchange Commission. 
 1.28 “SEC Rule 144” means Rule 144 promulgated by
the SEC under the Securities Act. 
 1.29 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 1.30 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.31 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the
sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.32 “Series A Director” means any director of the Company that the holders of record of the Series A Preferred
Stock are entitled to elect pursuant to the Restated Certificate. 
 1.33 “Series A Preferred Stock” means shares of the
Company’s Series A Preferred Stock, par value $0.0001 per share. 
 1.34 “Series B Director” means any
director of the Company that the holders of record of the Series B Preferred Stock are entitled to elect pursuant to the Restated Certificate. 

1.35 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share. 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) 4 years after the date of this
Agreement or (ii) 6 months after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $10.0 million, then the Company
shall (x) within 10 days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within 60 days
after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be
registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in
each case, subject to the limitations of Subsections 2.1(c), 2.1(d) and 2.3. 

  
 4 

 (b) Form S-3 Demand. If at any time when it
is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of Registrable Securities that the Company file a Form S-3 registration
statement with respect to the outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1 million, then the Company shall (i) within 10 days after the date such
request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c), 2.1(d) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection
2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to
either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization,
or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply
with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled
correspondingly, for a period of not more than 90 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any 12 month period; and provided further that the Company
shall not register any securities for its own account or that of any other stockholder during such 90 day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection
2.1(a) (i) if, within 30 days after receipt of a request for registration by the Initiating Holders pursuant to Section 2.1(a), the Company delivers notice to such Initiating Holders of its intent to file a
registration statement within 60 days of the date on which the Company received such request and the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective during such 60
day time period; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on
Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection
2.1(b) (i) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, a Company-initiated registration, provided that the
Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the 12 month
period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by
the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case
such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

  
 5 

 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the provisions of
Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under
this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall
be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing
underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would
be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 

  
 6 

 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering or (ii) the number of Registrable Securities included in the offering be
reduced below 25% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other
stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the
partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any
of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons
included in such “selling Holder,” as defined in this sentence. 
 (c) For purposes of Subsection 2.1, a registration shall
not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than 50% of the total number of Registrable Securities that Holders have requested to be included
in such registration statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if
earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period
the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120 day period shall be extended for up to 180 days, if necessary, to keep the registration
statement effective until all such Registrable Securities are sold; 
 (b) prepare and file with the SEC such amendments and supplements to
such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

  
 7 

 (c) furnish to the selling Holders such numbers of copies of a prospectus, including a
preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent
to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available for
inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

  
 8 

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the
Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and
the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all
selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to
one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or
prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and
shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid
by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 
 2.7 Delay of Registration.
No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of
this Section 2. 
 2.8 Indemnification. If any Registrable Securities are included in a registration
statement under this Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold
harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each
Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person
any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement
contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall
the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 

  
 9 

 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is
effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b)
and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any
governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been
given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one
counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due
to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such
action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure
to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case
(x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no
event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net
of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

  
 10 

 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file with
the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); and such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the
Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder to
include such securities in any registration if such agreement (a) would allow such holder or prospective holder to include a portion of its securities in any “piggyback” registration if such inclusion would reduce the number of
Registrable Securities that selling Holders could be entitled to include in such registration under Subsections 2.2 and 2.3(b) hereof or (b) would allow such holder or prospective holder to initiate a demand for registration of
any of its securities at a time earlier than the Holders of Registrable Securities can demand registration under Subsection 2.1 hereof; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in
accordance with Subsection 6.10. 

  
 11 

 2.11 “Market Stand-off” Agreement.
Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or
any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3 and ending on the date specified by the Company and the managing
underwriter (such period not to exceed 180 days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock (whether such shares or any such securities are then owned by the
Holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in
clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to
an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in
writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and
the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than 1% of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all
outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they
were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give
further effect thereto. Any discretionary waiver or termination of any “market stand-off” restrictions or any restrictions similar to those set forth in this Subsection 2.11 shall apply pro
rata to all Holders. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 

  
 12 

 (b) Each certificate, instrument, or book entry representing (i) the Preferred Stock,
(ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event,
shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE
SECURITIES LAWS, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF
COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR UNDER APPLICABLE STATE SECURITIES LAWS. 

THE SHARES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A
COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and giving
instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the
Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the
Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the
proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration
will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of
the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the
notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes
Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the
Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument,
or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

  
 13 

 2.13 Termination of Registration Rights. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) at such time following the IPO as a Holder holds less than 1% of the outstanding capital stock of the Company and Rule 144 or another
similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(b) the fifth anniversary of the QPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has
not reasonably determined that such Major Investor is a competitor of the Company; provided, further, that any Major Investor that is a financial investment firm shall not be deemed a competitor of the Company solely due to such Major
Investor’s investment in one or more competitors of the Company; provided, further, that none of Bayer HealthCare LLC and its Affiliates, New Enterprise Associates 15, Limited Partnership and its Affiliates (together,
“NEA”), 8VC Fund I, L.P. and its Affiliates (together, “8VC”), Pear Ventures II, L.P. and its Affiliates (“Pear”) or Lux Ventures IV, L.P. and its Affiliates (together, “Lux”) shall
be deemed a competitor of the Company for purposes of this Agreement: 
 (a) as soon as practicable, but in any event within 120 days after
the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all
such financial statements prepared in accordance with GAAP, all such financial statements audited and certified by independent public accountants selected by the Board of Directors, including at least one Series A Director and at least one Series B
Director, unless otherwise waived by the Board of Directors, including at least one Series A Director and at least one Series B Director; 

(b) as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each fiscal year of the
Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such
financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each fiscal year of the
Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or
exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for
issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; 

  
 14 

 (d) as soon as practicable, but in any event within 30 days of the end of each month, an
unaudited income statement and statement of cash flows for such month, and a comparison between (x) the actual amounts as of and for such month and (y) the comparable amounts for the prior month and as included in the Budget (as defined in
Subsection 3.1(e)) for such month, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such month, and an unaudited balance sheet and statement of stockholders’
equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes
thereto that may be required in accordance with GAAP); and 
 (e) as soon as practicable, but in any event 30 days before the end of each
fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after
prepared, any other budgets or revised budgets prepared by the Company. 
 If, for any period, the Company has any subsidiary whose accounts
are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such
consolidated subsidiaries. 
 Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing
the information set forth in this Subsection 3.1 during the period starting with the date 60 days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to
comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its
commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit
each Major Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company; provided, further, that any Major Investor that is a financial investment firm
shall not be deemed a competitor of the Company solely due to such Major Investor’s investment in one or more competitors of the Company; provided, further, that none of NEA, 8VC, Pear or Lux shall be deemed a competitor of the
Company for purposes of this Agreement), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its
officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any
information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely
affect the attorney-client privilege between the Company and its counsel. 
 3.3 Observer Rights. As long as (a) Bayer HealthCare
LLC and its Affiliates (together, “Bayer”) owns at least 1,826,261 shares of Preferred Stock or (b) NEA owns at least 2,005,289 shares of Preferred Stock (or, in each case, an equivalent amount of Common Stock issued upon
conversion thereof, but excluding shares of Common Stock issued upon conversion of the Preferred Stock pursuant to the “Special Mandatory Conversion” provisions of the Restated Certificate), the Company shall invite a representative
of Bayer and NEA, respectively, to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to
its directors at substantially the same time and in substantially the same manner as provided to such directors; provided, however, that such representative shall not be an employee of a competitor of the Company; provided,
further, that such representative shall agree to hold in confidence and trust with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such
representative from any meeting or portion thereof if, upon advice of the Company’s counsel, access to such information or attendance at such meeting would (i) adversely affect the attorney-client privilege between the Company and its
counsel, (ii) result in disclosure of trade secrets or (iii) result in an actual conflict of interest. 

  
 15 

 3.4 Termination of Information Rights. The covenants set forth in Subsection
3.1, Subsection 3.2 and Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting
requirements of Section 12(g) or 15(g) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, in which the consideration is cash and/or freely-tradeable and marketable securities, whichever event occurs first. 

3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement and, for
the avoidance of doubt, any information obtained pursuant to Sections 3.1 through 3.3 of this Agreement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this
Subsection 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a
third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants,
and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective
purchaser agrees to be bound by the provisions of this Subsection 3.5; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor
informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information, and provided, further, that notwithstanding anything to the contrary in this Agreement, Bayer
HealthCare LLC may not disclose any confidential information to BlueRock Therapeutics, LP; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to
minimize the extent of any such required disclosure. 
 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it, in such proportions as it
deems appropriate, among (i) itself and (ii) its Affiliates. 
 (a) The Company shall give notice (the “Offer
Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer
such New Securities. 

  
 16 

 (b) By notification to the Company within 20 days after the Offer Notice is given, each
Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor
(including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock
of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such 20 day period, the Company shall promptly notify each Major Investor that
elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the 10 day period commencing after the Company has given such
notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to
subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any
other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative
Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur no later than the later of 120 days following the date that the
Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 
 (c) If all New Securities
referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the 90 day period following the expiration of the periods provided in Subsection 4.1(b), offer and
sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an
agreement for the sale of the New Securities within such period, or if such agreement is not consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered
unless first reoffered to the Major Investors in accordance with this Subsection 4.1. 
 (d) The right of first offer in this
Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Restated Certificate); (ii) shares of Common Stock issued in the IPO in which all shares of Preferred Stock have converted into shares of Common Stock,
and (iii) the issuance of shares of Series B Preferred Stock pursuant to the Purchase Agreement. 
 (e) The right of first offer set
forth in this Subsection 4.1 (i) shall terminate with respect to any Major Investor immediately upon the conversion of the shares of Preferred Stock held by such Major Investor into shares of Common Stock pursuant to the “Special
Mandatory Conversion” provisions of the Restated Certificate, and (ii) shall not be applicable to any Major Investor if (A) at the time of such offering of New Securities, such Major Investor is not an “accredited
investor,” as such term is then defined in Rule 501(a) under the Securities Act, and (B) such New Securities are otherwise being offered only to accredited investors. 

  
 17 

 4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and
be of no further force or effect (i) immediately before the consummation of the QPO, or (ii) upon a Deemed Liquidation Event, in which the consideration is cash and/or freely tradeable and marketable securities, whichever event occurs
first and, with respect to each Major Investor, in accordance with Subsection 4.1(e)(i). 
 5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to maintain its Directors and Officers liability insurance on
terms and conditions reasonably satisfactory to the Board of Directors and in an amount equal to no less than $2,000,000 until such time as the Board of Directors determines that such insurance should be discontinued. 

5.2 Employee Agreements. The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the
Company or any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement or an employment or consulting agreement providing that (i) such person is either an at-will employee or a consultant of the Company, as the case may be, (ii) such person will maintain all Company proprietary information in confidence, (iii) such person will assign all inventions created
by him as an employee or consultant during his employment or service to the Company, and (iv) such person will not disclose any information related to the Company’s work force and will not solicit any employees from the Company for a
period of 12 months should his employment or service to the Company be terminated for any reason. 
 5.3 Employee Stock and Options.
Unless otherwise approved by the Board of Directors, including at least one Series A Director and at least one Series B Director, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of
shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four year period, with the first 25% of such shares
vesting following 12 months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following 36 months, and (ii) a market stand-off provision
substantially similar to that in Subsection 2.11. All option grants after the date hereof shall require the approval of the Board of Directors, including at least one Series A Director and at least one Series B Director. In addition, unless
otherwise approved by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of
employment of a holder of restricted stock. 
 5.4 Matters Requiring Preferred Director Approval. During such time or times as the
holders of Preferred Stock are entitled to elect a Preferred Director and such seat is filled, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must
include the affirmative vote of a majority of the Preferred Directors then serving: 
 (a) Make, or permit any subsidiary to make, any loan
or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

  
 18 

 (b) Make, or permit any subsidiary to make, any loan or advance to any Person, including,
without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business; 

(c) Guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d) Make any investment other than investments in
prime commercial paper, money market funds, certificates of deposit in any U.S. bank having a credit rating of at least A-2/A- by Moody’s Investors’ Service
and Standard & Poor’s or obligations issued or guaranteed by the U.S. government, in each case having a maturity not in excess of two years, unless such investment is made in accordance with the Company’s Investment Policy that
has been approved by a majority of the Preferred Directors; or 
 (e) Hire, terminate, or change the cash or equity compensation of the
executive officers, including approving any option grants or stock awards to executive officers. 
 5.5 Board Matters. Unless
otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the
non-employee directors and observers for all reasonable out-of-pocket travel expenses incurred (consistent with the
Company’s travel policy) in connection with attending meetings of the Board of Directors or any committee thereof and any other meetings or other activities attended on behalf of the Company at the Company’s request. Upon approval of the
Board of Directors, the Company shall cause to be established and will maintain, a compensation committee, for the purpose, among other things, of reviewing and determining the compensation of the Company’s executive officers, which shall
consist solely of non-management directors, including at least one Series A Director and at least one Series B Director. Each non-employee director shall be entitled in
such person’s discretion to be a member of any committee of the Board of Directors. 
 5.6 Successor Indemnification. If the
Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be
made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are
contained in the Company’s Bylaws, the Restated Certificate, or elsewhere, as the case may be. 
 5.7 Right to Conduct
Activities. The Company hereby agrees and acknowledges that certain of the Investors, including NEA, for the avoidance of doubt, are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed
competitive with the Company’s business (as currently conducted or as currently proposed to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, any such Investors shall not be liable to the Company for
any claim arising out of, or based upon, (i) the investment by such Investor in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of such Investor to assist any such competitive
company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall
not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement or otherwise, or (y) any director or officer of the Company
from any liability associated with his or her fiduciary duties to the Company. 

  
 19 

 5.8 Indemnification Matters. The Company hereby acknowledges that each of the
Preferred Directors may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and/or certain of its Affiliates (collectively, the “Fund Indemnitors”). The Company
hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to a Preferred Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or
liabilities incurred by a Preferred Director are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by a Preferred Director and shall be liable for the full amount of all expenses, judgments, penalties, fines
and amounts paid in settlement by or on behalf of any such Preferred Director to the extent legally permitted and as required by the Restated Certificate or Bylaws (or any agreement between the Company and a Preferred Director), without regard to
any rights a Preferred Director may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or
any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of a Preferred Director with respect to any claim for which a Preferred Director has sought
indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of a Preferred Director
against the Company. 
 5.9 Qualified Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of
Series A Preferred Stock and Series B Preferred Stock in the Initial Closing (as defined in the Purchase Agreement), as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Code, to constitute
“qualified small business stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors of the Company determines, in its good-faith business judgment,
that such qualification is inconsistent with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be required under
Section 1202(d)(1)(C) of the Internal Revenue Code (the “Code”) and the regulations promulgated thereunder. In addition, within 20 business days of the Company’s receipt of any Investor’s written request
therefor, the Company shall, at its option, either (i) deliver to such Investor a written statement indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as
defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such
Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. For the avoidance of doubt, the Company in no event shall be liable to the Investors or any other party
for any damages arising from any subsequently proven or identified error in any report or information provided to the Investors or such other party pursuant to this Subsection 5.9, unless such error is due to the gross negligence or fraud on the
part of the Company. 
 5.10 FIRPTA Compliance. The Company shall provide prompt notice to each Investor following any
“determination date” (as defined in Treasury Regulation Section 1.897-2(c)(1)) on which the Company becomes a United States real property holding corporation. In addition, within 20 business
days of the Company’s receipt of any Investor’s written request therefor, the Company shall provide such Investor with a written statement informing such Investor whether such Investor’s interest in the Company constitutes a United
States real property interest. The Company’s determination shall comply with the requirements of Treasury Regulation Section 1.897-2(h)(1) or any successor regulation, and the Company shall provide
timely notice to the Internal Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2) or any successor regulation, that such statement has been made.
The Company’s obligation to furnish such written statement shall continue notwithstanding the fact that a class of the Company’s stock may be traded on an established securities market or the fact that there is no preferred stock then
outstanding. Termination of Covenants. The covenants set forth in this Section 5, except for Subsection 5.6, shall terminate and be of no further force or effect (i) immediately before the consummation of the
QPO, or (ii) upon a Deemed Liquidation Event, whichever event occurs first. 

  
 20 

 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or
(iii) after such transfer, holds at least 2% of the Registrable Securities; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of
such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of
this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a
Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring
Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of
exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in
this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement,
except as expressly provided herein. 
 6.2 Governing Law. This Agreement shall be governed by the internal law of the State of
Delaware without regard to its choice of laws principles. 
 6.3 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 

  
 21 

 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.
All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this
Subsection 6.5. If notice is given to the Company, it shall be sent to Senti Biosciences, Inc., 2 Corporate Drive, First Floor, South San Francisco, California 94080, Attn: President, and a copy (which shall not constitute notice) shall also
be sent to Cooley LLP, 3175 Hanover Street Palo Alto, CA 94304, Attention: Michael E. Tenta, email mtenta@cooley.com, and if notice is given to the Investors, a copy (which shall not constitute notice) shall also be given to Orrick,
Herrington & Sutcliffe LLP, 405 Howard Street, San Francisco, CA 94105, Attention: Ramy Shweiky and via e-mail to rshweiky@orrick.com and to Fenwick & West LLP, 555 California Street,
12th Floor, San Francisco, CA 94104, Attention: Michael Brown and via e-mail to mbrown@fenwick.com. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided that the Company may
in its sole discretion waive compliance with Subsection 2.12(c); provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such
amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to
all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction) and (b) Sections 3.1 and 3.2,
Section 4 and any other section of this Agreement applicable to the Major Investors may be amended, modified, termination or waived with only the written consent of the Company and the holders of at least 60% of the Registrable Securities then
outstanding and held by the Major Investors. Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time without the consent of the other parties hereto (i) to add information regarding transferees of
any Registrable Securities in accordance with the terms of this Agreement and (ii) to add information regarding any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.10. The Company shall give
prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination, or waiver
effected in accordance with this Subsection 6.7 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one
or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 
 6.7
Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other
provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

  
 22 

 6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by
Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any recipient of such shares of Preferred Stock may become a party to this Agreement (without need for amendment or consent) by executing and delivering
an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such
additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including the Schedules and Exhibits hereto), the Restated Certificate and the other Transaction
Agreements (as defined in the Purchase Agreement) constitute the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof
existing between the parties is expressly canceled, including, for purposes of clarity, all provisions relating to the subject matter hereof contained in the Prior Agreement. Upon the effectiveness of this Agreement, the Prior Agreement shall be
deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
California and to the jurisdiction of the United States District Court for the Northern District of California for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any
suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of California or the United States District Court for the Northern District of California, and (c) hereby waive, and agree not to assert, by
way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that
the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE
OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT
RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH
OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

  
 23 

 Each of the parties to this Agreement consents to personal jurisdiction for any equitable
action sought in the U.S. District Court for the Northern District of California or any court of the State of California having subject matter jurisdiction. 

6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or
to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law
or otherwise afforded to any party, shall be cumulative and not alternative. 
 [Remainder of Page Intentionally Left Blank] 

  
 24 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	SENTI BIOSCIENCES, INC
		
	By:	 	/s/ Timothy Lu
	Name: Timothy Lu
	Title: Chief Executive Officer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	BAYER HEALTHCARE LLC
		
	By:	 	/s/ Kelly Gast
	Name:	 	Kelly Gast
	Title:	 	Senior VP and CFO Bayer US

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	 8VC ANGEL FUND I, L.P.

By: 8VC Angel GP I, LLC
 Its General
Partner

		
	By:	 	/s/ Ian Shannon
	Name:	 	Ian Shannon
	Title:	 	Authorized Signatory
	
	 8VC ANGEL FUND I ASSOCIATES, L.P.

By: 8VC Angel GP I, LLC
 Its General
Partner

		
	By:	 	/s/ Ian Shannon
	Name:	 	Ian Shannon
	Title:	 	Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	 8VC FUND I, L.P.
 By: 8VC
GP I, LLC
 Its General Partner

		
	By:	 	/s/ Ian Shannon
	Name:	 	Ian Shannon
	Title:	 	Authorized Signatory
	
	 8VC ENTREPRENEURS FUND I, L.P

By: 8VC GP I, LLC
 Its General Partner

		
	By:	 	/s/ Ian Shannon
	Name:	 	Ian Shannon
	Title:	 	Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	AMGEN VENTURES LLC
		
	By:	 	/s/ Janis C. Naeve
	Name:	 	Janis C. Naeve
	Title:	 	Executive Dir., Business Development

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LUX VENTURES IV, L.P.
	
	 By: Lux Venture Partners IV, LLC

Its: General Partner

		
	By:	 	/s/ Peter Hebert
	Name:	 	Peter Hebert
	Title:	 	Managing Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	NEW ENTERPRISE ASSOCIATES 15, L.P.
	
	 By: NEA Partners 15, L.P., its general partner

Its: NEA 15 GP, LLC, its general partner

		
	By:	 	/s/ Louis Citron
	Name:	 	Louis Citron
	Title:	 	Chief Legal Officer
	
	NEA VENTURES 2018, L.P.
	
	 By: Louis S. Citron
 Its: Vice
President

		
	By:	 	/s/ Louis Citron
	Name:	 	Louis Citron
	Title:	 	Chief Legal Officer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTORS:
	
	BRYAN WHITE
	
	/s/ Bryon White

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	CNSA LLC
		
	By:	 	/s/ Chuck Clarvit
	Name:	 	Chuck Clarvit
	Title:	 	Authorized Person

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	GRIDS VENTURES I, LTD
		
	By:	 	/s/ Guy Perelmuter
	Name:	 	Guy Perelmuter
	Title:	 	Investment Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	GAINGELS SENTI BIO LLC
		
	By:	 	/s/ David Beatty
	Name:	 	David Beatty
	Title:	 	Manager, Gaingels LLC, a Managing Member

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	KB GROWTH CAPITAL FUND
	
	By: KB Investment Co., its general partner
		
	By:	 	 /s/ Jong Pil Kim

	Name:	 	Jong Pil Kim
	Title:	 	Chief Executive Officer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LIFESCI VENTURE PARTNERS II, LP
		
	By:	 	 /s/ Paul Yook

	Name:	 	Paul Yook
	Title:	 	Managing Member of the GP

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LOBBY 7 CAPITAL LLC
		
	By:	 	 /s/ Sina Kevin Nazemi

	Name:	 	Sina Kevin Nazemi
	Title:	 	Chief Executive Officer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTORS:
	
	IBRAHIM SAMIR ELTATAWY
	
	 /s/ Ibrahim Samir Eltatawy

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTORS:
	
	AltoIRA Empire Trust Custodian FBO Sina Nazemi Roth IRA
	
	SINA KEVIN NAZEMI IRA
	
	 /s/ Eric Satz

	Eric Satz, CEO

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	KOREA INVESTMENT & SECURITIES CO., LTD
	
	not in its corporate capacity but solely in its capacity as trustee on behalf of SMILEGATE ORCHARD FUND 3
		
	By:	 	 /s/ Jung, Il-Mun

	Name:	 	Jung, Il-Mun
	Title:	 	President

 DISCLAIMER: KOREA INVESTMENT & SECURITIES CO., LTD. has executed this Agreement in its capacity as the
trustee of SMILEGATE ORCHARD FUND 3 per the instruction of Smilegate Asset Management Inc. acting as the collective investment company. Any result or outcome arising from any act or exercise of a right by KOREA INVESTMENT & SECURITIES CO.,
LTD., or the collective investment company shall be deemed to have occurred in respect of SMILEGATE ORCHARD FUND 3 and the aggregate liabilities of KOREA INVESTMENT & SECURITIES CO., LTD., and the collective investment company under this
Agreement shall be limited to the assets of SMILEGATE ORCHARD FUND 3. Nothing in this disclaimer shall have the effect of limiting or restricting any liability of KOREA INVESTMENT & SECURITIES CO., LTD., or the collective investment company
arising as a result of any fraud, negligence or willful misconduct on the part of KOREA INVESTMENT & SECURITIES CO., LTD., or the collective investment company, respectively. 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	 SMILEGATE DEEPTECH FUND 1

(Smilegate Investment, Inc.)

		
	By:	 	 /s/ Ki Moon Nam

	Name:	 	Ki Moon Nam
	Title:	 	Chief Executive Officer
	
	 SMILEGATE PATHFINDER FUND

(Smilegate Investment, Inc.)

		
	By:	 	 /s/ Ki Moon Nam

	Name:	 	Ki Moon Nam
	Title:	 	Chief Executive Officer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	SE FUND I, a series of Noveus Capital Funds, LP
	
	 By: Fund GP, LLC its General Partner

By: Belltower Fund Group, Ltd. Manager of the General Partner

		
	By:	 	 /s/ Brett Sagan

	Name:	 	Brett Sagan
	Title:	 	Authorized Person of the Manager of the Fund’s GP

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	PEAR VENTURES II, L.P.
	
	 By: Pear Ventures GP II, LLC
 Its:
General Partner

		
	By:	 	 /s/ Pejman Nozad

	Name:	 	Pejman Nozad
	Title:	 	Managing Director
	
	PEAR VENTURES OPPORTUNITIES IX, LLC.
	
	 By: Pear Ventures Opportuntities Management, LLC

Its: General Partner

		
	By:	 	 /s/ Pejman Nozad

	Name:	 	Pejman Nozad
	Title:	 	Managing Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	 MIRAE ASSET-CELLTRION NEW

GROWTH FUND I

	
	Mirae Asset Capital, Its General Partner
		
	By:	 	 /s/ Ji Kwang Chung

	Name:	 	Ji Kwang Chung
	Title:	 	Managing Director
	
	MIRAE ASSET CAPITAL, INC
	
	MIRAE ASSET CAPITAL, INC.
		
	By:	 	 /s/ Ji Kwang Chung

	Name:	 	Ji Kwang Chung
	Title:	 	Managing Director
	
	MIRAE ASSET-NAVER NEW GROWTH FUND I
	
	Mirae Asset Capital, Its General Partner
		
	By:	 	 /s/ Ji Kwang Chung

	Name:	 	Ji Kwang Chung
	Title:	 	Managing Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	 MENLO VENTURES XIV, L.P..

MENLO ENTREPRENEURS FUND XIV, L.P.
 MMEF XIV,
L.P.

	
	 By: MV Management XIV, L.L.C
 Their:
General Partner

		
	By:	 	 /s/ Mark Siegel

	Name:	 	Mark Siegel
	Title:	 	Managing Member

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	ADENA PARTNERS I, L.P.
		
	By:	 	 /s/ Hao Cui

	Name:	 	Hao Cui
	Title:	 	Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LIFEFORCE CAPITAL OPPORTUNITY FUND, L.P.
	
	By: LifeForce Capital Opportunity Fund GP, LLC, its General Partner
		
	By:	 	 /s/ John Noonan

	Name:	 	John Noonan
	Title:	 	Managing Partner

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	 ALEXANDRIA VENTURE INVESTMENTS, LLC,

a Delaware limited liability company

	
	 By: ALEXANDRIA REAL ESTATE EQUITIES, INC.,

    a Maryland corporation, managing member

		
	By:	 	 /s/ Aaron Jacobson

	Name:	 	Aaron Jacobson
	Title:	 	SVP – Venture Counsel

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	PURCHASERS:
	
	INTEL CAPITAL CORPORATION
		
	By:	 	/s/ Abhay Gadkari
	Name:	 	Abhay Gadkari
	Title:	 	Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	PURCHASERS:
	
	RIDGEBACK CAPITAL INVESTMENTS LP
	
	 By: Ridgeback Capital Management LLC

Its: Investment Manager

		
	By:	 	/s/ Christian Sheldon
	Name:	 	Christian Sheldon
	Title:	 	CTO

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	PURCHASERS:
	
	SE FUND I, A SERIES OF ANGELLIST -GP- FUNDS-I, LP
	
	 By: Fund GP, LLC, its General Partner

By: Belltower Fund Group, Ltd., Manager of the General Partner

		
	By:	 	/s/ Meghan Christenson
	Name:	 	Meghan Christenson
	Title:	 	Authorized Person

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	PURCHASERS:
	
	MATRIX PARTNERS CHINA VI HONG KONG LIMITED
		
	By:	 	/s/ David Ying Zhang
	Name:	 	David Ying Zhang
	Title:	 	Director

 SCHEDULE A 

Investors 
  

	
	Bayer HealthCare LLC
	
	New Enterprise Associates 15, L.P.
	
	NEA Ventures 2018, Limited Partnership
	
	8VC Fund I, L.P.
	
	8VC Entrepreneurs Fund I, L.P.
	
	8VC Angel Fund I, LP
	
	8VC Angel Fund I Associates, LP
	
	Lux Ventures IV, L.P.
	
	Bryan White
	
	CNSA LLC
	
	GRIDS Ventures I, Ltd
	
	Amgen Ventures LLC
	
	Korea Investment & Securities CO., LTD 
as the trustee on behalf of 
SMILEGATE ORCHARD FUND 3
	
	Smilegate Deeptech Fund I
	
	Smilegate Pathfinder Fund
	
	Mirae Asset-Celltrion New Growth Fund I
	
	Mirae Asset Capital, Inc.
	
	Mirae Asset-Naver New Growth Fund I
	
	KB Growth Capital Fund
	
	Lobby 7 Capital LLC
	
	AltoIRA Empire Trust Custodian FBO Sina Nazemi Roth IRA
	
	Ibrahim Samir Eltatawy
	
	Pear Ventures II, L.P.
	
	Pear Ventures Opportunities IX, LLC.

	
	Menlo Ventures XIV, L.P.
	
	Menlo Entrepreneurs Fund XIV, L.P.
	
	MMEF XIV, L.P.
	
	Adena Partners I, L.P.
	
	LifeForce Capital Opportunity Fund, LLC
	
	Alexandria Venture Investments, LLC
	
	Gaingels Senti Bio LLC
	
	SE Fund I, a series of Noveus Capital Funds, LP
	
	LifeSci Venture Partners II, LP
	
	Jason Fuller
	
	Nest Bio WO Senti Bio LP
	
	Omega Cambridge SPV L.P.
	
	The Nishar Family Children’s Trust dtd 12/2/2009
	
	MATOE LLC
	
	Goodman Capital USA Pte. Ltd.
	
	Donald Tang
	
	Kinglord Corporation
	
	Timothy Lu
	
	William Sahlman
	
	Allen & Company LLC
	
	Brian Davis
	
	Julia DimonEX-10.2

 Exhibit 10.2 

SENTI BIOSCIENCES, INC. 

NOTICE OF EXERCISE OF OPTION 
 To: Senti
Biosciences, Inc. 
 This is to notify Senti Biosciences, Inc., a Delaware corporation (the “Company”), that I hereby
irrevocably elect to exercise the right to purchase the number of shares of the Company’s common stock, par value $0.0001 per share, indicated below. Such shares are being purchased pursuant to my exercise of an option (the
“Option”) granted to me under the Company’s 2016 Stock Incentive Plan and pursuant to an [Incentive/Non-Statutory] Stock Option Agreement
dated                            . 

Option and Exercise: 
 Per Share
Exercise Price: $             
 Number of Shares Purchased: 

Total Exercise Price:
$                                         
                            (number of shares purchased multiplied by per share exercise price) 

As payment for the shares, enclosed is a certified or bank check payable to the order of “Senti Biosciences,
Inc.” in the sum of $                     . 

I hereby confirm that I have read and I fully understand the terms and conditions of the Company’s 2016 Stock Incentive Plan. 

 

							
	  
	 		 		 	  

	(Signature)	 		 		 	(Street Address)
				
	  
	 		 		 	  

	(Print Name)	 		 		 	(CIty State, Zip Code)
				
	  
	 		 		 	  

	(Date)	 		 		 	(E-mail Address)

 SENTI BIOSCIENCES, INC. 

INVESTMENT LETTER 
 To: Senti Biosciences, Inc.

  

	 	Re:	 Purchase of Common Stock 

Ladies and Gentlemen: 
 This investment letter is
executed and delivered to Senti Biosciences, Inc., a Delaware corporation (the “Company”), in connection with my purchase of
                        shares of common stock of the Company, par value $0.0001 per share (the
“Shares”). 
 The Shares are being purchased pursuant to my exercise of an option granted to me under the Company’s
2016 Stock Incentive Plan (the “Plan”) and pursuant to an [Incentive/Non-Statutory] Stock Option Agreement dated
                     (the “Option Agreement”). 

I understand that the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or
registered or qualified under the securities or “blue sky” laws of any state or jurisdiction, and are being sold to me pursuant to exemptions contained in the Securities Act and exemptions contained in other applicable securities or
“blue sky” laws. I represent and warrant that the offer and sale of the Shares was made solely in the state shown in the address set forth below. I hereby represent to the Company, and agree that the Company is entitled to rely on such
representations, that I am acquiring the Shares with no intention of reselling any of them in any distribution within the meaning of the Securities Act. Specifically, I represent to the Company (i) that I am acquiring the Shares for my own
account, and only with a view to investment in, and not for, in connection with or with a view to the disposition of, the Shares, (ii) that no one else has any beneficial ownership in the Shares, (iii) that the Shares are not subject to
any pledge or other lien, and (iv) that I do not intend to and will not resell the Shares unless, at a future date, they are registered under the Securities Act or a specific exemption from registration is available to me in connection with
such resale. The nature and amount of my investment in the Shares are consistent with my investment objectives, abilities and resources. I understand that the Shares are an illiquid investment, which will not become freely transferable by reason of
any “change of circumstances” whatsoever. I have adequate means of providing for my current needs and possible contingencies and have no need for liquidity in my investment. 

I understand that the Shares will constitute “restricted securities” within the meaning of Rule l44 promulgated under the Securities
Act and that, as such, the Shares must be held indefinitely unless they are subsequently registered under the Securities Act or unless an exemption from the registration requirements thereof is available. 

I hereby acknowledge and agree that (i) the Shares shall continue to be bound by the terms and conditions of the Option Agreement and the
terms of the Plan, and (ii) in addition to any restrictions on transfer pursuant to any applicable law, the Share are and will remain subject to restrictions on transfer imposed pursuant to the Plan and the Option Agreement. Without limiting
the generality of the foregoing, I acknowledge that the Shares shall be subject to that certain right of first refusal in favor of the Company which is described in the Option Agreement. 

  
 2 

 I acknowledge and agree that in addition to legends required or permitted pursuant to the
Plan and the Option Agreement, the certificate representing the Shares will bear a legend in substantially the following form: 

“THE SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR UNDER
THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE PLEDGED, HYPOTHECATED, SOLD OR OTHERWISE TRANSFERRED UNLESS SUCH SHARES HAVE BEEN REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY, IN FORM
AND SUBSTANCE SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED. 
 “ANY DISPOSITION OF ANY INTEREST
IN THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO RESTRICTIONS, AND THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN OPTIONS, CONTAINED IN A CERTAIN AGREEMENT BETWEEN THE RECORD HOLDER HEREOF AND THE COMPANY, A
COPY OF WHICH WILL BE MAILED TO ANY HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON RECEIPT BY THE COMPANY OF A WRITTEN REQUEST THEREFOR.” 

I acknowledge and agree that the Company may place a stop order pertaining to the certificates evidencing the Shares with any transfer agent
of the Company, to the same effect as the above legend. The legend and stop transfer notice referred to above shall be removed only upon my furnishing to the Company an opinion of counsel to the effect that such legend may lawfully be removed and if
such counsel and such opinion are satisfactory to the Company. 
 I have consulted my attorney or my accountant with respect to my purchase
of the Shares. My representatives and I have fully investigated the Company and its business and financial conditions and have knowledge of the Company’s current corporate activities and financial condition. I acknowledge that the Company has
granted me and my attorney or accountant access to all information about the Company which I have requested and has offered each of us access to all further information which I deemed relevant to an investment decision with respect to the Shares. My
attorney or accountant and I have had the opportunity to ask questions of, and receive answers from, representatives of the Company concerning such information and the Company’s financial condition and prospects. 

Very truly yours, 
  

							
	  
	 		 		 	  

	(Signature)	 		 		 	(Address)
				
	  
	 		 		 	  

	(Print Name)	 		 		 	(Address)
				
	  
	 		 		 	  

	(Date)	 		 		 	(E-mail Address)

  
 3 

 INCENTIVE STOCK OPTION 

Granted by 
 Senti Biosciences,
Inc. (the “Company”) 
 Under the 2016 Stock Incentive Plan 

This Option is and shall be subject in every respect to the provisions of the Company’s 2016 Stock Incentive Plan, as amended from time
to time (the “Plan”), which is incorporated herein by reference and made a part hereof. The holder of this Option (the “Holder”) hereby accepts this Option subject to all the terms and provisions of the Plan and agrees that
(a) in the event of any conflict between the terms hereof and those of the Plan, the latter shall prevail, and (b) all decisions under and interpretations of the Plan by the Board or the Committee shall be final, binding and conclusive
upon the Holder and his or her heirs and legal representatives. 
  

							
	1.	  		  	Name of Holder:	  	as described on Carta
				
	2.	  		  	Date of Grant:	  	as described on Carta
			
	3.	  		  	Maximum number of shares for
		  	which this Option is exercisable:	  	as described on Carta
			
	4.	  		  	Exercise (purchase) price per share:
		  		  	as described on Carta

  

	5.	 Method of Exercise: This Option may be exercised by the delivery of written notice to the Company
setting forth the number of shares with respect to which the Option is to be exercised, together with payment by one of the following methods: 

cash or a personal, certified or bank check or postal money order payable to the order of the Company for an amount equal to the exercise price
of the shares being purchased; or 
 with the consent of the Company, any of the other methods set forth in the Plan. 

As an additional condition to exercise of this Option, the Holder shall deliver to the Company an investment letter in form and
substance satisfactory to the Company and its counsel. No such investment letter shall be required as a condition to such exercise at any time when there shall be an effective registration statement under the Securities Act of 1933, as amended (the
“Act”) covering the shares for which this Option may be exercised. 
  

	6.	
                       
                                         
                                        
Expiration Date of Option: as described on Carta 

  
 4 

	7.	 Vesting Schedule: This Option shall become exercisable for 25% of the maximum number of shares granted
on the first anniversary of the Date of Grant, and shall become exercisable for an additional 2.08331/3% of the maximum number of shares granted on the last day of each one month period thereafter; so that the Option shall be fully vested on the
fourth anniversary of the Date of Grant. All vesting shall cease upon the date of termination of employment. 

  

	8.	 Termination of Employment. This Option shall terminate on the earliest to occur of:

  

	 	(i)	 the date of expiration hereof; 

 

	 	(ii)	 0 days after termination of the Holder’s employment with the Company by the Company for Cause (as defined
in the Plan); 

  

	 	(iii)	 90 days after the date of voluntary termination of employment by the Holder (other than for death or permanent
and total disability as defined in the Plan); 

  

	 	(iv)	 90 days after the date of termination of the Holder’s employment with the Company by the Company without
Cause (other than for death or permanent and total disability as defined in the Plan); or 

  

	 	(v)	 one year after the “permanent and total disability” (as defined at Section 10 of the Plan) or
death of the Holder. 

  

	6.	 Company’s Right of First Refusal. Prior to the effective date of a registration statement under the
Act, any shares of stock issued pursuant to exercise of this Option shall be subject to the Company’s right of first refusal as set forth at Appendix A. 

  

	7.	 Lock-Up Agreement. The Holder agrees that upon the request of the Company or the managing underwriter(s)
of any offering of securities of the Company that is the subject of a registration statement filed under the Act, for a period of time (not to exceed 180 days) from the effective date of the registration statement under the Act for such offering,
the Holder will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares of Common Stock issued pursuant to the exercise of this Option, without the prior written consent of the Company and
such underwriters. 

  

	8.	 Incentive Stock Option; Disqualifying Disposition. Although this Option is intended to qualify as an
incentive stock option under the Internal Revenue Code of 1986 (the “Code”), the Company makes no representation as to the tax treatment upon exercise of this Option or sale or other disposition of the shares covered by this Option, and
the Holder is advised to consult a personal tax advisor. Upon a Disqualifying Disposition of shares received upon exercise of this Option, the Holder will forfeit the favorable income tax treatment otherwise available with respect to the exercise of
this Option. A “Disqualifying Disposition” shall have the meaning specified in Section 421(b) of the Code; as of the date of grant of this Option a Disqualifying Disposition is any disposition (including any sale) of such shares
before the later of (a) the second anniversary of the date of grant of this Option and (b) the first anniversary of the date on which the Holder acquired such shares by exercising this Option, provided that such holding period requirements
terminate upon the death of the Holder. The Holder shall notify the Company in writing immediately upon making a Disqualifying Disposition of any shares of Common Stock received pursuant to the exercise of this Option, and shall provide the Company
with any information that the Company shall request concerning any such Disqualifying Disposition. 

  
 5 

	9.	 Voting Agreement. Reference is made to that certain Voting Agreement, dated January 9, 2018, by and
among the Company and the other parties thereto, as may be amended or amended and restated from time to time (the “Voting Agreement”). As a condition precedent to the Company being obligated to issue shares of Common Stock upon exercise of
this Option, the Holder shall become a party to the Voting Agreement by executing the Adoption Agreement (Voting) attached hereto as Exhibit A , whereby Holder agrees to be bound by and subject to the terms and provisions of such Voting Agreement as
a Stockholder (as defined therein) and thereafter Holder shall be deemed a “Stockholder” for all purposes under the Voting Agreement. 

  

	10.	 Notice. Any notice to be given to the Company hereunder shall be deemed sufficient if addressed to the
Company and delivered to the office of the Company, Senti Biosciences, Inc., 2 Corporate Drive, 1st Floor, South San Francisco, CA 94080, attention of the president, or such other address as the Company may hereafter designate.

 Any notice to be given to the Holder hereunder shall be deemed sufficient if addressed to and delivered in person to the
Holder at his or her address furnished to the Company or when deposited in the mail, postage prepaid, addressed to the Holder at such address. 

IN WITNESS WHEREOF, the parties have executed this Option, or caused this Option to be executed, as of the Date of Grant. 

 

			
	SENTI BIOSCIENCES, INC.
		
	By:	 	
                 

 The undersigned Holder hereby acknowledges receipt of a copy of the Plan and this Option (including Appendix A hereto),
and agrees to the terms of this Option and the Plan. 
  

	
	  

	Holder

  
 6 

 APPENDIX A 

Right of First Refusal 

1. General. Prior to the effective date of a registration statement under the Securities Act of 1933, as amended (the “Act”),
covering any shares of the Company’s Common Stock and until such time as the Company shall have effected a public offering of its Common Stock registered under the Act, in the event that, at any time when the Holder (which term for purposes of
this section shall mean the Holder and his or her executors, administrators and any other person to whom this Option may be transferred by will or the laws of descent and distribution) is permitted to do so, the Holder desires to sell, assign or
otherwise transfer any of the shares issued upon the exercise of this Option, the Holder shall first offer such shares to the Company by giving written notice of the Holder’s desire so to sell, assign or transfer such shares. 

2. Notice of Intended Transfer. The notice shall state the number of shares offered, the name of the person or persons to whom it is
proposed to sell, assign or transfer such shares and the price at which such shares are intended to be sold, assigned or transferred. Such notice shall constitute an offer to the Company for the Company to purchase the number of shares set forth in
the notice at a price per share equal to the price stated therein. 
 3. Company to Accept or Decline Within 30 Days. The Company may
accept the offer as to all, but not less than all, such shares by notifying the Holder in writing within 30 days after receipt of such notice of its acceptance of the offer. If the offer is accepted, the Company shall have 60 days after such
acceptance within which to purchase the offered shares at a price per share as aforesaid. If within the applicable time periods the Holder does not receive notice of the Company’s intention to purchase the offered shares, or if payment in full
of the purchase price is not made by the Company, the offer shall be deemed to have been rejected and the Holder may transfer title to such shares within 90 days from the date of the Holder’s written notice to the Company of the Holder’s
intention to sell, but such transfer shall be made only to the proposed transferee and at the proposed price as stated in such notice and after compliance with any other provisions of this Option applicable to the transfer of such shares. 

4. Transferred Shares to Remain Subject to Right of First Refusal. Shares that are so transferred to such transferee shall remain
subject to the rights of the Company set forth in this Appendix A. As a condition to such transfer, such transferee shall execute and deliver all such documents as the Company may require to evidence the binding agreement of such transferee so to
remain subject to the rights of the Company. 
 5. Remedies of Company. No sale, assignment, pledge or other transfer of any of the
shares covered by this Option shall be effective or given effect on the books of the Company unless all of the applicable provisions of this Appendix A have been duly complied with, and the Company may inscribe on the face of any certificate
representing any of such shares a legend referring to the provisions of this Appendix A. If any transfer of shares is made or attempted in violation of the foregoing restrictions, or if shares are not offered to the Company as required hereby, the
Company shall have the right to purchase such shares from the owner thereof or his transferee at any time before or after the transfer, as herein provided. In addition to any other legal or equitable remedies which it may have, the Company may
enforce its rights by actions for specific performance (to the extent permitted by law) and may refuse to recognize any transferee as one of its stockholders for any purpose, including, without limitation, for purposes of dividend and voting rights,
until all applicable provisions hereof have been complied with. 

  
 7 

 6. Shares Subject to Right of First Refusal. For purposes of the Right of First
Refusal pursuant to this Appendix A, the term “shares” shall mean any and all new, substituted or additional securities or other property issued to the Holder, by reason of his or her ownership of Common Stock pursuant to the exercise of
this Option, in connection with any stock dividend, liquidating dividend, stock split or other change in the character or amount of any of the outstanding securities of the Company, or any consolidation, merger or sale of all or substantially all of
the assets of the Company. 
 7. Legends on Stock Certificates. Any certificate representing shares of stock subject to the provisions
of this Appendix A may have endorsed thereon one or more legends, substantially as follows: 
  

	 	(i)	 “Any disposition of any interest in the securities represented by this certificate is subject to
restrictions, and the securities represented by this certificate are subject to certain options, contained in a certain agreement between the record holder hereof and the Company, a copy of which will be mailed to any holder of this certificate
without charge upon receipt by the Company of a written request therefor.” 

  

	 	(ii)	 “The shares of stock represented by this certificate have not been registered under the Securities Act of
1933 or under the securities laws of any state and may not be pledged, hypothecated, sold or otherwise transferred unless such shares have been registered under the Act or unless the Company has received an opinion of counsel satisfactory to the
Company, in form and substance satisfactory to the Company, that such registration is not required.” 

 3. Right
of First Refusal to Lapse Upon Registration. The restrictions imposed by this Appendix A shall terminate in all respects upon the effective date of a registration statement under the Act covering any of the Company’s Common Stock. 

  
 8 

 EXHIBIT A 

ADOPTION AGREEMENT 
 This
Adoption Agreement (“Adoption Agreement”) is executed on                     , 20__, by the undersigned (the
“Holder”) pursuant to the terms of that certain Voting Agreement dated as of January 9, 2018 (the “Agreement “), by and among the Company and certain of its Stockholders, as such Agreement may be amended or
amended and restated hereafter. Capitalized terms used but not defined in this Adoption Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Holder agrees as follows.

 1.1 Acknowledgement . Holder acknowledges that Holder has been granted certain options to purchase shares of capital stock of the
Company (the “Options”), and in accordance with Subsection 7.1(b) of the Agreement, Holder hereby agrees to be bound by and subject to the terms of the Agreement as a “Stockholder”, and shall be deemed a
“Stockholder” for all purposes of the Agreement. 
 1.2 Agreement. Holder hereby (a) agrees that the Options, any
shares of capital stock of the Company issued to the Holder upon exercise of the Options, and any other shares of capital stock or securities required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement
and (b) adopts the Agreement with the same force and effect as if Holder were originally a party thereto. 
 1.3 Notice . Any
notice required or permitted by the Agreement shall be given to Holder at the address or facsimile number listed below Holder’s signature hereto. 
  

							
	HOLDER:	 		 		 	ACCEPTED AND AGREED:
				
		 		 		 	SENTI BIOSCIENCES, INC.
				
	Print or Type Name of Signatory	 		 		 	
				
	Address:	 		 		 	By:
				
		 		 		 	Title:
				
	Phone Number:	 		 		 	

  
 9 

 NON-STATUTORY STOCK OPTION 

Granted by 
 Senti Biosciences,
Inc. (the “Company”) 
 Under the 2016 Stock Incentive Plan 

This Option is and shall be subject in every respect to the provisions of the Company’s 2016 Stock Incentive Plan, as amended from time
to time (the “Plan”), which is incorporated herein by reference and made a part hereof. The holder of this Option (the “Holder”) hereby accepts this Option subject to all the terms and provisions of the Plan and agrees that
(a) in the event of any conflict between the terms hereof and those of the Plan, the latter shall prevail, and (b) all decisions under and interpretations of the Plan by the Board or the Committee shall be final, binding and conclusive
upon the Holder and his or her heirs and legal representatives. 
  

	1.	 Name of Holder: 

 

	2.	 Date of Grant: 

 

	3.	 Maximum number of shares for 

which this Option is exercisable: 
  

	4.	 Exercise (purchase) price per share: [must be at least fair market value]

  

	5.	 Method of Exercise: This Option may be exercised by the delivery of written notice to the Company
setting forth the number of shares with respect to which the Option is to be exercised, together with payment by one of the following methods: 

cash or a personal, certified or bank check or postal money order payable to the order of the Company for an amount equal to the exercise price
of the shares being purchased; or 
 with the consent of the Company, any of the other methods set forth in the Plan. 

[Note: in the alternative, may specify methods allowed] 

As an additional condition to exercise of this Option, the Holder shall deliver to the Company an investment letter in form and
substance satisfactory to the Company and its counsel. No such investment letter shall be required as a condition to such exercise at any time when there shall be an effective registration statement under the Securities Act of 1933, as amended (the
“Act”) covering the shares for which this Option may be exercised. 
  

	6.	 Expiration Date of Option: 

  
 10 

	7.	 Vesting Schedule: [Note: Company to elect vesting schedule; following is an example of a standard
vesting provision] This Option shall become exercisable for 25% of the maximum number of shares granted on the first anniversary of the Date of Grant, and shall become exercisable for an additional
2.08331⁄3% of the maximum number of shares granted on the last day of each one month period thereafter; so that the Option shall be fully vested on the fourth
anniversary of the Date of Grant. All vesting shall cease upon the date of termination of employment or provision of services. 

  

	8.	 Termination of Employment. This Option shall terminate on the earliest to occur of:

  

	 	(i)	 the date of expiration thereof; 

 

	 	(ii)	 0 days after termination of the Holder’s employment with or services to the Company by the Company for
Cause (as defined in the Plan); 

  

	 	(iii)	 90 days after the date of voluntary termination of employment or services by the Holder (other than for death
or permanent and total disability as defined in the Plan); 

  

	 	(iv)	 90 days after the date of termination of the Holder’s employment with or services to the Company by the
Company without Cause (other than for death or permanent and total disability as defined in the Plan); or 

  

	 	(v)	 one year after the “permanent and total disability”(as defined at Section 10 of the Plan) or
death of the Holder. 

  

	9.	 Company’s Right of First Refusal. Prior to the effective date of a registration statement under the
Act, any shares of stock issued pursuant to exercise of this Option shall be subject to the Company’s right of first refusal as set forth at Appendix A. 

  

	10.	 Lock-Up Agreement. The Holder agrees that upon the request of the Company or the managing underwriter(s)
of any offering of securities of the Company that is the subject of a registration statement filed under the Act, for a period of time (not to exceed 180 days) from the effective date of the registration statement under the Act for such offering,
the Holder will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares of Common Stock issued pursuant to the exercise of this Option, without the prior written consent of the Company and
such underwriters. 

  

	11.	 Tax Withholding. The Company’s obligation to deliver shares shall be subject to the Holder’s
satisfaction of any federal, state and local income and employment tax withholding requirements. 

  

	12.	 Notice. Any notice to be given to the Company hereunder shall be deemed sufficient if addressed to the
Company and delivered to the office of the Company, Senti Biosciences, Inc., 1106 Bay St., Alameda, CA 94501, attention of the president, or such other address as the Company may hereafter designate. 

  
 11 

 Any notice to be given to the Holder hereunder shall be deemed sufficient if addressed to
and delivered in person to the Holder at his or her address furnished to the Company or when deposited in the mail, postage prepaid, addressed to the Holder at such address. 

IN WITNESS WHEREOF, the parties have executed this Option, or caused this Option to be executed, as of the Date of Grant. 

 

			
	SENTI BIOSCIENCES, INC.
		
	By:	 	          

 The undersigned Holder hereby acknowledges receipt of a copy of the Plan and this Option (including Appendix A hereto),
and agrees to the terms of this Option and the Plan. 
  

	
	  

	Holder

  
 12 

 APPENDIX A 

Right of First Refusal 

1. General. Prior to the effective date of a registration statement under the Securities Act of 1933, as amended (the “Act”),
covering any shares of the Company’s Common Stock and until such time as the Company shall have effected a public offering of its Common Stock registered under the Act, in the event that, at any time when the Holder (which term for purposes of
this section shall mean the Holder and his or her executors, administrators and any other person to whom this Option may be transferred by will or the laws of descent and distribution) is permitted to do so, the Holder desires to sell, assign or
otherwise transfer any of the shares issued upon the exercise of this Option, the Holder shall first offer such shares to the Company by giving written notice of the Holder’s desire so to sell, assign or transfer such shares. 

2. Notice of Intended Transfer. The notice shall state the number of shares offered, the name of the person or persons to whom it is
proposed to sell, assign or transfer such shares and the price at which such shares are intended to be sold, assigned or transferred. Such notice shall constitute an offer to the Company for the Company to purchase the number of shares set forth in
the notice at a price per share equal to the price stated therein. 
 3. Company to Accept or Decline Within 30 Days. The Company may
accept the offer as to all, but not less than all, such shares by notifying the Holder in writing within 30 days after receipt of such notice of its acceptance of the offer. If the offer is accepted, the Company shall have 60 days after such
acceptance within which to purchase the offered shares at a price per share as aforesaid. If within the applicable time periods the Holder does not receive notice of the Company’s intention to purchase the offered shares, or if payment in full
of the purchase price is not made by the Company, the offer shall be deemed to have been rejected and the Holder may transfer title to such shares within 90 days from the date of the Holder’s written notice to the Company of the Holder’s
intention to sell, but such transfer shall be made only to the proposed transferee and at the proposed price as stated in such notice and after compliance with any other provisions of this Option applicable to the transfer of such shares. 

4. Transferred Shares to Remain Subject to Right of First Refusal. Shares that are so transferred to such transferee shall remain
subject to the rights of the Company set forth in this Appendix A. As a condition to such transfer, such transferee shall execute and deliver all such documents as the Company may require to evidence the binding agreement of such transferee so to
remain subject to the rights of the Company. 
 5. Remedies of Company. No sale, assignment, pledge or other transfer of any of the
shares covered by this Option shall be effective or given effect on the books of the Company unless all of the applicable provisions of this Appendix A have been duly complied with, and the Company may inscribe on the face of any certificate
representing any of such shares a legend referring to the provisions of this Appendix A. If any transfer of shares is made or attempted in violation of the foregoing restrictions, or if shares are not offered to the Company as required hereby, the
Company shall have the right to purchase such shares from the owner thereof or his transferee at any time before or after the transfer, as herein provided. In addition to any other legal or equitable remedies which it may have, the Company may
enforce its rights by actions for specific performance (to the extent permitted by law) and may refuse to recognize any transferee as one of its stockholders for any purpose, including, without limitation, for purposes of dividend and voting rights,
until all applicable provisions hereof have been complied with. 

  
 13 

 6. Shares Subject to Right of First Refusal. For purposes of the Right of First
Refusal pursuant to this Appendix A, the term “shares” shall mean any and all new, substituted or additional securities or other property issued to the Holder, by reason of his or her ownership of Common Stock pursuant to the exercise of
this Option, in connection with any stock dividend, liquidating dividend, stock split or other change in the character or amount of any of the outstanding securities of the Company, or any consolidation, merger or sale of all or substantially all of
the assets of the Company. 
 7. Legends on Stock Certificates. Any certificate representing shares of stock subject to the provisions
of this Appendix A may have endorsed thereon one or more legends, substantially as follows: 
  

	 	(i)	 “Any disposition of any interest in the securities represented by this certificate is subject to
restrictions, and the securities represented by this certificate are subject to certain options, contained in a certain agreement between the record holder hereof and the Company, a copy of which will be mailed to any holder of this certificate
without charge upon receipt by the Company of a written request therefor.” 

  

	 	(ii)	 “The shares of stock represented by this certificate have not been registered under the Securities Act of
1933 or under the securities laws of any state and may not be pledged, hypothecated, sold or otherwise transferred unless such shares have been registered under the Act or unless the Company has received an opinion of counsel satisfactory to the
Company, in form and substance satisfactory to the Company, that such registration is not required.” 

 8. Right of
First Refusal to Lapse Upon Registration. The restrictions imposed by this Appendix A shall terminate in all respects upon the effective date of a registration statement under the Act covering any of the Company’s Common Stock. 

  
 14 

 Exhibit 10.2 

SENTI BIOSCIENCES, INC. 

AMENDED AND RESTATED 

2016 STOCK INCENTIVE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS: JULY 25, 2016 

APPROVED BY THE STOCKHOLDERS: JULY 28, 2016 

AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 9, 2018 

APPROVED BY THE STOCKHOLDERS: FEBRUARY 9, 2018 

AMENDED BY THE BOARD OF DIRECTORS: OCTOBER 20, 2020 

APPROVED BY THE STOCKHOLDERS: OCTOBER 20, 2020 

AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 28, 2021 

APPROVED BY THE STOCKHOLDERS: APRIL 4, 2021 

AMENDED BY THE BOARD OF DIRECTORS: DECEMBER 19, 2021 
  

	 	1.	 Purpose. 

The purpose of this plan (the “Plan”) is to secure for Senti Biosciences, Inc., a Delaware corporation (the “Company”) and
its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary corporations who are expected to contribute to the Company’s
future growth and success. Under the Plan recipients may be awarded both (i) Options (as defined in Section 2.1) to purchase the Company’s common stock, par value $0.0001 (“Common Stock”) and (ii) shares of Common Stock
(“Restricted Stock Awards”). Except where the context otherwise requires, the term “Company” shall include any parent and all present and future subsidiaries of the Company as defined in Sections 424(e) and 424(f) of the Internal
Revenue Code of 1986, as amended or replaced from time to time (the “Code”). Those provisions of the Plan which make express reference to Section 422 of the Code shall apply only to Incentive Stock Options (as that term is defined
below). Appendix A to this Plan shall apply only to participants in the Plan who are residents of the State of California. 
  

	 	2.	 Types of Awards and Administration. 

2.1 Options. Options granted pursuant to the Plan (“Options”) shall be authorized by action of the Board of Directors of the
Company (the “Board” or “Board of Directors”) and may be either incentive stock options (“Incentive Stock Options”) meeting the requirements of Section 422 of the Code or non-statutory Options which are not
intended to meet the requirements of Section 422. All Options when granted are intended to be non-statutory Options, unless the applicable Option Agreement (as defined in Section 5.1) explicitly states that the Option is intended to be an
Incentive Stock Option. The vesting of Options may be conditioned upon the completion of a specified period of employment with the Company and/or such other conditions or events as the Board may determine. The Board may also provide that Options are
immediately exercisable subject to certain repurchase rights in the Company dependent upon the continued employment of the optionee and/or such other conditions or events as the Board may determine. 

  
 1 

 2.1.1 Incentive Stock Options. Incentive Stock Options may only be granted to
employees of the Company. For so long as the Code shall so provide, Options granted to any employee under the Plan (and any other incentive stock option plans of the Company) which are intended to constitute Incentive Stock Options shall not
constitute Incentive Stock Options to the extent that such Options, in the aggregate, become exercisable for the first time in any one calendar year for shares of Common Stock with an aggregate fair market value (determined as of the respective date
or dates of grant) of more than $100,000. If an Option is intended to be an Incentive Stock Option, and if for any reason such Option (or any portion thereof) shall not qualify as an Incentive Stock Option, then, to the extent of such
nonqualification, such Option (or portion thereof) shall be regarded as a non-statutory Option appropriately granted under the Plan provided that such Option (or portion thereof) otherwise meets the Plan’s requirements relating to non-statutory
Options. 
 2.2 Restricted Stock Awards. The Board in its discretion may grant Restricted Stock Awards, entitling the recipient to
acquire, for a purchase price determined by the Board, shares of Common Stock subject to such restrictions and conditions as the Board may determine at the time of grant (“Restricted Stock”), including continued employment and/or
achievement of pre-established performance goals and objectives. 
 2.3 Administration. The Plan shall be administered by the Board,
whose construction and interpretation of the terms and provisions of the Plan shall be final and conclusive. The Board may in its sole discretion authorize issuance of Restricted Stock, the grant of Options and the issuance of shares upon exercise
of such Options as provided in the Plan. The Board shall have authority, subject to the express provisions of the Plan, to construe Restricted Stock Agreements, Option Agreements and the Plan, to prescribe, amend and rescind rules and regulations
relating to the Plan, to determine the terms and provisions of Restricted Stock Agreements and Option Agreements, and to make all other determinations in the judgment of the Board necessary or desirable for the administration of the Plan. The Board
may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any Restricted Stock Agreement or Option Agreement in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be
the sole and final judge of such expediency. No director or person acting pursuant to authority delegated by the Board shall be liable for any action or determination under the Plan made in good faith. The Board may, to the full extent permitted by
or consistent with applicable laws or regulations, delegate any or all of its powers under the Plan to a committee (the “Committee”) appointed by the Board, and if the Committee is so appointed, to the extent of such delegation, all
references to the Board in the Plan shall mean and relate to such Committee, other than references to the Board in this sentence and in Section 18 (as to amendment or termination of the Plan) and Section 22. 

 

	 	3.	 Eligibility. 

Options may be granted, and Restricted Stock may be issued, to persons who are, at the time of such grant or issuance, employees, officers or
directors of, or consultants or advisors to, the Company; provided, that the class of persons to whom Incentive Stock Options may be granted shall be limited to employees of the Company. 

  
 2 

 3.1 10% Shareholder. If any employee to whom an Incentive Stock Option is to be
granted is, at the time of the grant of such Option, the owner of stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (after taking into account the attribution of stock ownership rules of
Section 424(d) of the Code) (a “Greater Than 10% Shareholder”), any Incentive Stock Option granted to such individual must: (i) have an exercise price per share of not less than 110% of the fair market value of one share of
Common Stock at the time of grant; and (ii) expire by its terms not more than five years from the date of grant. 
  

	 	4.	 Stock Subject to Plan. 

Subject to adjustment as provided in Section 14.2 below, the maximum number of shares of Common Stock which may be issued under the Plan
is 65,551,165 shares, all of which may be issued with respect to Incentive Stock Options. If an Option shall expire or terminate for any reason without having been exercised in full, the unpurchased shares subject to such Option shall again be
available for subsequent Option grants or Restricted Stock Awards under the Plan. If shares of Restricted Stock shall be forfeited to, or otherwise repurchased by, the Company pursuant to a Restricted Stock Agreement, such repurchased shares shall
again be available for subsequent Option grants or Restricted Stock Awards under the Plan. If shares otherwise issuable upon exercise of an Option are withheld by the Company in payment of the exercise price of an Option or to satisfy tax
withholding obligations with respect to such exercise, such withheld shares shall again be available for subsequent Option grants or Restricted Stock Awards under the Plan. 
  

	 	5.	 Forms of Restricted Stock Agreements and Option Agreements. 

5.1 Option Agreement. Each recipient of an Option shall execute an option agreement (“Option Agreement”) in such form not
inconsistent with the Plan as may be approved by the Board of Directors. Such Option Agreements may differ among recipients. 
 5.2
Restricted Stock Agreement. Each recipient of a grant of Restricted Stock shall execute an agreement (“Restricted Stock Agreement”) in such form not inconsistent with the Plan as may be approved by the Board of Directors. Such
Restricted Stock Agreements may differ among recipients. 
 5.3 “Lock-Up” Agreement. Unless the Board specifies otherwise,
each Restricted Stock Agreement and Option Agreement shall provide that upon the request of the Company or the managing underwriter(s) of any offering of securities of the Company that is the subject of a registration statement filed under the
United States Securities Act of 1933, as amended from time to time (the “Act”), the holder of any Option or the purchaser of any Restricted Stock shall, in connection therewith, agree in writing (in such form as the Company or such
managing underwriter(s) shall request) to the general effect that for a period of time (not to exceed 180 days) from the effective date of the registration statement under the Act for such offering, the holder or purchaser will not sell, make any
short sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares of the common stock of the Company owned or controlled by him or her. 

  
 3 

	 	6.	 Purchase Price. 

6.1 General. The purchase price per share of Restricted Stock and per share of stock deliverable upon the exercise of an Option shall be
determined by the Board, provided, however, that in the case of any Option, the exercise price shall not be less than 100% of the fair market value of such stock, as determined by the Board, at the time of grant of such Option, or less than 110% of
such fair market value in the case of any Incentive Stock Option granted to a Greater Than 10% Shareholder. 
 6.2 Payment of Purchase
Price. Option Agreements may provide for the payment of the exercise price by delivery of cash or a check to the order of the Company in an amount equal to the exercise price of such Options, or, to the extent provided in the applicable Option
Agreement, by one of the following methods: 
 (i) with the consent of the Board, by delivery to the Company of shares of
Common Stock; such surrendered shares shall have a fair market value equal in amount to the exercise price of the Options being exercised, 

(ii) with the consent of the Board, a personal recourse note issued by the optionee to the Company in a principal amount equal
to such aggregate exercise price and with such other terms, including interest rate and maturity, as the Company may determine in its discretion; provided, however, that the interest rate borne by such note shall not be less than the lowest
applicable federal rate, as defined in Section 1274(d) of the Code, 
 (iii) with the consent of the Board, if the class
of Common Stock is registered under the Securities Exchange Act of 1934 at such time, subject to rules as may be established by the Board, by delivery to the Company of a properly executed exercise notice along with irrevocable instructions to a
broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price, 

(iv) with the consent of the Board, by reducing the number of Option shares otherwise issuable to the optionee upon exercise of
the Option by a number of shares of Common Stock having a fair market value equal to such aggregate exercise price, 
 (v)
with the consent of the Board, by any combination of such methods of payment. 
 The fair market value of any shares of Common Stock or
other non-cash consideration which may be delivered upon exercise of an Option shall be determined by the Board of Directors. Restricted Stock Agreements may provide for the payment of any purchase price in any manner approved by the Board of
Directors at the time of authorizing the issuance thereof. 

  
 4 

	 	7.	 Option Period. 

Notwithstanding any other provision of the Plan or any Option Agreement, each Option and all rights thereunder shall expire on the date
specified in the applicable Option Agreement, provided that such date shall not be later than ten years after the date on which the Option is granted (or five years in the case of an Incentive Stock Option granted to a Greater Than 10% Shareholder),
and in either case, shall be subject to earlier termination as provided in the Plan or Option Agreement. 
  

	 	8.	 Exercise of Options. 

8.1 General. Each Option shall be exercisable either in full or in installments at such time or times and during such period as shall be
set forth in the Option Agreement evidencing such Option, subject to the provisions of the Plan. To the extent not exercised, installments shall accumulate and be exercisable, in whole or in part, at any time after becoming exercisable, but not
later than the date the Option expires. 
 8.2 Notice of Exercise. An Option may be exercised by the optionee by delivering to the
Company on any business day a written notice specifying the number of shares of Common Stock the optionee then desires to purchase and specifying the address to which the certificates for such shares are to be mailed (the “Notice”),
accompanied by payment for such shares. In addition, the Company may require any individual to whom an Option is granted, as a condition of exercising such Option, to give written assurances (the “Investment Letter”) in a substance and
form satisfactory to the Company to the effect that such individual is acquiring the Common Stock subject to the Option for his or her own account for investment and not with a view to the resale or distribution thereof, and to such other effects as
the Company deems necessary or advisable in order to comply with any securities law(s). 
 8.3 Delivery. As promptly as practicable
after receipt of the Notice, the Investment Letter (if required) and payment, the Company shall deliver or cause to be delivered to the optionee certificates for the number of shares with respect to which such Option has been so exercised, issued in
the optionee’s name; provided, however, that such delivery shall be deemed effected for all purposes when the Company or a stock transfer agent shall have deposited such certificates in the United States mail, addressed to the optionee, at the
address specified in the Notice. 
  

	 	9.	 Nontransferability of Options. 

No Option shall be assignable or transferable by the person to whom it is granted, either voluntarily or by operation of law, except by will or
the laws of descent and distribution. During the life of an optionee, an Option shall be exercisable only by the optionee. 

  
 5 

 10. Termination of Employment; Disability; Death. Except as may be otherwise
expressly provided in the terms and conditions of the Option Agreement, Options shall terminate on the earliest to occur of: 
  

	 	(i)	 the date of expiration thereof; 

 

	 	(ii)	 0 days after termination of the optionee’s employment with, or provision of services to, the Company by
the Company for Cause (as hereinafter defined); 

  

	 	(iii)	 90 days after the date of voluntary termination of the optionee’s employment with, or provision of
services to, the Company by the optionee (other than for death or permanent disability as defined below); or 

  

	 	(iv)	 90 days after the date of termination of the optionee’s employment with, or provision of services to, the
Company by the Company without Cause (other than for death or permanent disability as defined below). 

 Until the date on which the
Option so expires, the optionee may exercise that portion of his or her Option which is exercisable at the time of termination of the employment or service relationship. 

An employment or service relationship between the Company and the optionee shall be deemed to exist during any period during which the
optionee is employed by or providing services to the Company. Whether an authorized leave of absence or an absence due to military or government service shall constitute termination of the employment relationship between the Company and the optionee
shall be determined by the Board at the time thereof. 
 For purposes of this Section 10, the term “Cause” shall mean
(a) any material breach by the optionee of any agreement to which the optionee and the Company are both parties, (b) any act (other than retirement) or omission to act by the optionee which may have a material and adverse effect on the
Company’s business or on the optionee’s ability to perform services for the Company, including, without limitation, the commission of any crime (other than minor traffic violations), or (c) any material misconduct or material neglect
of duties by the optionee in connection with the business or affairs of the Company. An optionee’s employment shall be deemed to have been terminated for Cause if the Company determines within thirty (30) days of the termination of
employment (whether such termination was voluntary or involuntary) that termination for Cause was warranted. 
 In the event of the
permanent and total disability or death of an optionee while in an employment or other relationship with the Company, any Option held by such optionee shall terminate on the earlier of the date of expiration of the Option or one year following the
date of such disability or death. After disability or death, the optionee (or in the case of death, his or her executor, administrator or any person or persons to whom this option may be transferred by will or by laws of descent and distribution)
shall have the right, at any time prior to such termination 

  
 6 

 
of an Option , to exercise the Option to the extent the optionee was entitled to exercise such Option as of the date of his or her disability or death. An optionee is permanently and totally
disabled if he or she is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to last for a continuous period of not less than 12 months; permanent and total
disability shall be determined in accordance with Section 22(e)(3) of the Code and the regulations issued thereunder. 
 5. Rights as
a Shareholder. The holder of an Option shall have no rights as a shareholder with respect to any shares covered by the Option (including, without limitation, any rights to receive dividends or non-cash distributions with respect to such shares)
until the date of issue of a stock certificate to him or her for such shares. No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued. 

6. Additional Provisions. The Board of Directors may, in its sole discretion, include additional provisions in Restricted Stock
Agreements and Option Agreements, including, without limitation, restrictions on transfer, rights of the Company to repurchase shares of Restricted Stock or shares of Common Stock acquired upon exercise of Options, commitments to pay cash bonuses,
to make, arrange for or guaranty loans or to transfer other property to optionees upon exercise of Options, or such other provisions as shall be determined by the Board of Directors; provided that such additional provisions
shall not be inconsistent with any other term or condition of the Plan and such additional provisions shall not be such as to cause any Incentive Stock Option to fail to qualify as an Incentive Stock Option within the meaning of Section 422 of
the Code. 
 7. Acceleration, Extension, Etc. The Board of Directors may, in its sole discretion, (i) accelerate the date
or dates on which all or any particular Option or Options may be exercised or (ii) extend the period or periods of time during which all, or any particular, Option or Options may be exercised. 

 

	 	8.	 Adjustment Upon Changes in Capitalization 

14.1 No Effect of Options upon Certain Corporate Transactions. The existence of outstanding Options shall not affect in any way the
right or power of the Company to make or authorize any or all adjustments, recapitalizations, reorganizations or other changes in the Company’s capital structure or its business, or any merger or consolidation, or any issue of Common Stock, or
any issue of bonds, debentures, preferred or prior preference stock ahead of or affecting the Common Stock or the rights thereof, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business,
or any other corporate act or proceeding, whether of a similar character or otherwise. 

  
 7 

 14.2 Adjustment Provisions. If, through or as a result of any merger, consolidation,
sale of all or substantially all of the assets of the Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar transaction, (i) the outstanding shares of Common Stock are
increased, decreased or exchanged for a different number or kind of shares or other securities of the Company, or (ii) additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with
respect to such shares of Common Stock or other securities, an appropriate and proportionate adjustment shall be made in (x) the maximum number and kind of shares reserved for issuance under the Plan, (y) the number and kind of shares or
other securities subject to any then outstanding Options, and (z) the price for each share or other security subject to any then outstanding Options, so that upon exercise of such Options, in lieu of the shares of Common Stock for which such
Options were then exercisable, the relevant optionee shall be entitled to receive, for the same aggregate consideration, the same total number and kind of shares or other securities, cash or property that the owner of an equal number of outstanding
shares of Common Stock immediately prior to the event requiring adjustment would own as a result of the event. If any such event shall occur, appropriate adjustment shall also be made in the application of the provisions of this Section 14 and
Section 15 with respect to Options and the rights of optionees after the event so that the provisions of such Sections shall be applicable after the event and be as nearly equivalent as practicable in operation after the event as they were
before the event. 
 14.3 No Adjustment in Certain Cases. Except as hereinbefore expressly provided, the issue by the Company of
shares of stock of any class, or securities convertible into shares of stock of any class, for cash or property or for labor or services, either upon direct sale or upon the exercise of rights or warrants to subscribe therefor, or upon conversion of
shares or obligations of the Company convertible into such shares or other securities, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock then subject to outstanding
options. 
 14.4 Board Authority to Make Adjustments. Any adjustments under this Section 14 will be made by the Board of
Directors, whose determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued under the Plan on account of any such adjustments. 

 

	 	15.	 Effect of Certain Transactions 

15.1 General. Except as provided in any Option Agreement or Restricted Stock Agreement to the contrary, if the Company is merged with or
into or consolidated with another corporation under circumstances where the stockholders of the Company immediately prior to such merger or consolidation do not own after such merger or consolidation shares representing at least fifty percent
(50%) of the voting power of the Company or the surviving or resulting corporation, as the case may be, or if shares representing fifty percent (50%) or more of the voting power of the Company are transferred to an Unrelated Third Party,
as hereinafter defined, or if the Company is liquidated, or sells or otherwise disposes of all or substantially all its assets (each such transaction is referred to herein as a “Change in Control Transaction”), the Board, or the board of
directors of any corporation assuming the obligations of the Company, may, in its discretion, take any one or more of the following actions, as to some or all outstanding Options or Restricted Stock Awards (and need not take the same action as to
each such Option or Restricted Stock Award): (i) provide that such Options shall be assumed, or equivalent Options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), provided that any such Options
substituted for Incentive Stock Options shall meet the requirements of 

  
 8 

 
Section 424(a) of the Code, (ii) upon written notice to the optionees, provide that all unexercised Options (whether vested or unvested) will terminate immediately prior to the
consummation of the Change in Control Transaction unless exercised by the optionee to the extent otherwise then exercisable within a specified period following the date of such notice, (iii) upon written notice to the grantees, provide that all
unvested shares of Restricted Stock shall be repurchased at cost, (iv) make or provide for a cash payment to the optionees equal to the difference between (A) the fair market value of the per share consideration (whether cash, securities
or other property or any combination of the above) the holder of a share of Common Stock will receive upon consummation of the Change in Control Transaction (the “Per Share Transaction Price”) times the number of shares of Common Stock
subject to outstanding vested Options (to the extent then exercisable at prices not equal to or in excess of the Per Share Transaction Price) and (B) the aggregate exercise price of such outstanding vested Options, in exchange for the
termination of such Options, or (v) provide that all or any outstanding Options shall become exercisable and all or any outstanding Restricted Stock Awards shall vest in part or in full immediately prior to such event. To the extent that any
Options are exercisable at a price equal to or in excess of the Per Share Transaction Price, the Board may provide that such Options shall terminate immediately upon the consummation of the Change in Control Transaction without any payment being
made to the holders of such Options. “Unrelated Third Party” shall mean any person who is not, on the date of adoption of this Plan by the Board, a holder of stock of any class or preference or any stock option of the Company. 

15.2 Substitute Options. The Company may grant Options in substitution for options held by employees, officers or directors of, or
consultants or advisors to, another corporation who become employees, officers or directors of, or consultants or advisors to, the Company, as the result of a merger or consolidation of the employing corporation with the Company or as a result of
the acquisition by the Company of property or stock of the employing corporation. The Company may direct that substitute Options be granted on such terms and conditions as the Board considers appropriate in the circumstances. 

15.3 Restricted Stock. In the event of a business combination or other transaction of the type detailed in Section 15.1, any
securities, cash or other property received in exchange for shares of Restricted Stock shall continue to be governed by the provisions of any Restricted Stock Agreement pursuant to which they were issued, including any provision regarding vesting,
and such securities, cash, or other property may be held in escrow on such terms as the Board of Directors may direct, to insure compliance with the terms of any such Restricted Stock Agreement. 

16. No Special Employment Rights. Nothing contained in the Plan or in any Option Agreement or Restricted Stock Agreement shall confer
upon any optionee or holder of Restricted Stock any right with respect to the continuation of his or her employment by the Company or interfere in any way with the right of the Company at any time to terminate such employment or to increase or
decrease his or her compensation. 

  
 9 

 17. Other Employee Benefits. The amount of any compensation deemed to be received by
an employee as a result of the issuance of shares of Restricted Stock or the grant or exercise of an Option or the sale of shares received upon issuance of a Restricted Stock Award or exercise of an Option will not constitute compensation with
respect to which any other employee benefits of such employee are determined, including, without limitation, benefits under any bonus, pension, profit-sharing, life insurance or salary continuation plan, except as otherwise specifically determined
by the Board of Directors. 
  

	 	18.	 Amendment of the Plan. 

18.1 The Board may at any time, and from time to time, modify or amend in any respect or terminate the Plan. If shareholder approval is not
obtained within twelve months after any amendment increasing the number of shares authorized under the Plan or changing the class of persons eligible to receive Options under the Plan, no Options granted pursuant to such amendments shall be deemed
to be Incentive Stock Options and no Incentive Stock Options shall be issued pursuant to such amendments thereafter. 
 18.2 The termination
or any modification or amendment of the Plan shall not, without the consent of an optionee or the holder of Restricted Stock, adversely affect his or her rights under an Option or Restricted Stock Award previously granted to him or her. With the
consent of the recipient of Restricted Stock or optionee affected, the Board may amend outstanding Restricted Stock Agreements or Option Agreements in a manner not inconsistent with the Plan. 

19. Withholding. The Company shall have the right to deduct from payments of any kind otherwise due to the optionee or recipient of
Restricted Stock, any federal, state or local taxes of any kind required by law to be withheld with respect to issuance of any shares of Restricted Stock or shares issued upon exercise of Options. Prior to delivery of any Common Stock pursuant to
the terms of this Plan, the Board has the right to require that the optionee or recipient of Restricted Stock remit to the Company an amount sufficient to satisfy any minimum tax withholding obligation. Subject to the prior approval of the Company,
which may be withheld by the Company in its sole discretion, the obligor may elect to satisfy any minimum withholding obligations, in whole or in part, (i) by causing the Company to withhold shares of Common Stock otherwise issuable, or
(ii) by delivering to the Company a sufficient number of shares of Common Stock. The shares so withheld shall have a fair market value equal to such minimum withholding obligation. The fair market value of the shares used to satisfy such
minimum withholding obligation shall be determined by the Company as of the date that the amount of tax to be withheld is to be determined. A person who has made an election pursuant to this Section 19 may only satisfy his or her withholding
obligation with shares of Common Stock which are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar restrictions. 

  
 10 

	 	20.	 Effective Date and Duration of the Plan. 

20.1 Effective Date. The Plan shall become effective when adopted by the Board of Directors. If shareholder approval is not obtained
within twelve months after the date of the Board’s adoption of the Plan, no Options previously granted under the Plan shall be deemed to be Incentive Stock Options and no Incentive Stock Options shall be granted thereafter. Amendments to the
Plan not requiring shareholder approval shall become effective when adopted by the Board. Amendments requiring shareholder approval shall become effective when adopted by the Board, but if shareholder approval is not obtained within twelve months of
the Board’s adoption of such amendment, any Incentive Stock Options granted pursuant to such amendment shall be deemed to be non-statutory Options provided that such Options are authorized by the Plan. Subject to this limitation, Options may be
granted under the Plan at any time after the effective date and before the date fixed for termination of the Plan. 
 20.2
Termination. Unless sooner terminated by action of the Board of Directors, the Plan shall terminate upon the close of business on the day next preceding the tenth anniversary of the date of its adoption by the Board of Directors. 

21. Provision for Foreign Participants. The Board of Directors may, without amending the Plan, modify the terms of Option Agreements or
Restricted Stock Agreements to differ from those specified in the Plan with respect to participants who are foreign nationals or employed outside the United States to recognize differences in laws, rules, regulations or customs of such foreign
jurisdictions with respect to tax, securities, currency, employee benefit or other matters. 
 22. Requirements of Law. The
Company shall not be required to sell or issue any shares under any Option or Restricted Stock Award if the issuance of such shares shall constitute a violation by the optionee, the Restricted Stock Award recipient, or by the Company of any
provision of any law or regulation of any governmental authority. In addition, in connection with the Act, the Company shall not be required to issue any shares upon exercise of any Option unless the Company has received evidence satisfactory to it
to the effect that the holder of such Option will not transfer such shares except pursuant to a registration statement in effect under the Act or unless an opinion of counsel satisfactory to the Company has been received by the Company to the effect
that such registration is not required in connection with any such transfer. Any determination in this connection by the Board shall be final, binding and conclusive. In the event the shares issuable on exercise of an Option are not registered under
the Act or under the securities laws of each relevant state or other jurisdiction, the Company may imprint on the certificate(s) appropriate legends that counsel for the Company considers necessary or advisable to comply with the Act or any such
state or other securities law. The Company may register, but in no event shall be obligated to register, any securities covered by the Plan pursuant to the Act; and in the event any shares are so registered the Company may remove any legend on
certificates representing such shares. The Company shall not be obligated to take any affirmative action in order to cause the exercise of an Option, the grant of any Restricted Stock Award or the issuance of shares pursuant thereto to comply with
any law or regulation of any governmental authority. 
 23. Conversion of Incentive Stock Options into Non-Qualified Options;
Termination. The Board of Directors, with the consent of any optionee, may in its discretion take such actions as may be necessary to convert such optionee’s Incentive Stock Options (or any installments or portions of installments thereof)
that have not been exercised on the date of conversion into non-statutory Options at any time prior to the expiration of such Incentive Stock Options, regardless of whether the optionee is an employee of the Company or a parent or

  
 11 

 
subsidiary of the Company at the time of such conversion. At the time of such conversion, the Board of Directors (with the consent of the optionee) may impose such conditions on the exercise of
the resulting non-statutory Options as the Board of Directors in its discretion may determine, provided that such conditions shall not be inconsistent with this Plan. Nothing in this Plan shall be deemed to give any optionee the right to have such
optionee’s Incentive Stock Options converted into non-statutory Options, and no such conversion shall occur until and unless the Board of Directors takes appropriate action. The Board of Directors, with the consent of the optionee, may also
terminate any portion of any Incentive Stock Option that has not been exercised at the time of such termination. 
 24. Non-Exclusivity of
this Plan; Non-Uniform Determinations. Neither the adoption of this Plan by the Board of Directors nor the approval of this Plan by the stockholders of the Company shall be construed as creating any limitations on the power of the Board of
Directors to adopt such other incentive arrangements as it may deem desirable, including, without limitation, the granting of stock options otherwise than under this Plan, and such arrangements may be either applicable generally or only in specific
cases. 
 The determinations of the Board of Directors under this Plan need not be uniform and may be made by it selectively among
persons who receive or are eligible to receive Options or Restricted Stock Awards under this Plan (whether or not such persons are similarly situated). Without limiting the generality of the foregoing, the Board of Directors shall be entitled, among
other things, to make non-uniform and selective determinations, and to enter into non-uniform and selective Option Agreements and Restricted Stock Agreements, as to (a) the persons to receive Options or Restricted Stock Awards under this Plan,
(b) the terms and provisions of Options or Restricted Stock Awards, (c) the exercise by the Board of Directors of its discretion in respect of the exercise of Options pursuant to the terms of this Plan, and (d) the treatment of leaves
of absence pursuant to Section 10 hereof. 
 25. Governing Law. This Plan and each Option or Restricted Stock Award shall be
governed by the laws of the state of Delaware, without regard to its principles of conflicts of law. 

  
 12 

 APPENDIX A 

TO SENTI BIOSCIENCES, INC. 2016 STOCK INCENTIVE PLAN 

FOR CALIFORNIA RESIDENTS ONLY 

This Appendix to the Senti Biosciences, Inc. 2016 Stock Incentive Plan (the “Plan”) shall have application only to participants in
the Plan who are residents of the State of California. Capitalized terms contained herein shall have the same meanings given to them in the Plan, unless otherwise provided in this Appendix. Notwithstanding any provision contained in the Plan to
the contrary and to the extent required by applicable law, the following terms and conditions shall apply to all Options and Restricted Stock Awards (collectively “Awards”) granted to residents of the State of California, until such time
as the Common Stock becomes subject to registration under the Securities Act of 1933: 
 1. Awards shall be nontransferable other than by
will or the laws of descent and distribution. Notwithstanding the foregoing, and to the extent permitted by Section 422 of the Code, the Board, in its discretion, may permit distribution of an Award to an inter vivos or testamentary trust in
which the Award is to be passed to beneficiaries upon the death of the trustor (settlor), or by gift to “immediate family” as that term is defined in Rule 16a-1(e) of the United States Exchange Act of 1934. 

2. Unless employment is terminated for Cause, the right to exercise an Option in the event of termination of employment, to the extent that the
optionee is otherwise entitled to exercise an Option on the date employment terminates, shall be 
 (a) at least six months from the date of
termination of employment if termination was caused by death or permanent disability; and 
 (b) at least 30 days from the date of
termination if termination of employment was caused by other than death or permanent disability; 
 (c) but in no event later than the
remaining term of the Option. 
 3. Any Award exercised before shareholder approval is obtained shall be rescinded if shareholder approval is
not obtained within 12 months of the Board’s adoption of the Plan. 

  
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]